Cooperative Research Agreements Related to the World Trade Center Health Program (U01)
Open
Centers for Disease Control and Prevention - ERA is offering grants of up to $550,000 to any type of organization. It expects to make about 30 awards worth $49.5 million in total. Applications close on December 8, 2026.
From the official notice on Grants.gov, last changed October 7, 2026. Checked October 31, 2026.
- Award ceiling$550,000
- Award floornot stated
- Expected awards30
- Total funding$49.5 million
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | May 8, 2026 |
|---|---|
| Deadline | December 8, 2026 |
| Archived by Grants.gov | October 27, 2027 |
Add the deadline to your calendar
Who can apply
This opportunity is open to any type of organization.
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Is this a realistic fit?
- No cost sharing or match is required.
What the grant funds
The National Institute for Occupational Safety and Health (NIOSH) supports research projects that address: (1) physical and mental health conditions related to the September 11, 2001, terrorist attacks; (2) diagnosing conditions for which there has been diagnostic uncertainty; and (3) treating conditions for which there has been treatment uncertainty. Conditions may have emerged since the treatment program began or since the WTC Health Program was established. This announcement solicits meritorious and scientifically rigorous applications that will: 1) improve diagnosis and treatment activities of the WTC Health Program; 2) expand knowledge about health effects related to the September 11, 2001, terrorist attacks; 3) answer critical questions about WTC-related physical and mental health conditions; and 4) apply lessons learned to improve response to future disasters. Potential projects may include, but are not limited to: (a) Screening research to evaluate current methods or facilitate the development of new or improved methods to detect disorders or health conditions; (b) Diagnostic research to evaluate current methods or facilitate the development of new or improved methods to identify diseases, disorders, or conditions; (c) Treatment research to evaluate or identify improved treatment interventions or methods, or to promote development of new or novel approaches; (d) Prevention research to identify or evaluate methods and interventions that prevent or mitigate the development or recurrence of diseases or disorders; (e) Quality of life research to identify, develop, or evaluate methods or interventions that improve comfort and quality of life for individuals with chronic illness or multimorbidity; (f) Omics research to improve methods for predicting disorders by identifying and understanding relationships between genes and illness (e.g., phenotypes and biomarkers), including how genetic factors influence disease development or response to treatment; (g) Epidemiologic or clinical research to identify patterns, causes, and control of adverse health effects among the 9/11-exposed population; (h) Health services research to examine access to care, cost of care, and outcomes associated with care delivery; (i) Implementation research to evaluate how research findings are disseminated, adopted, implemented, sustained, and scaled in real-world settings; and (j) Epidemiologic research to investigate emerging conditions where preliminary data suggest, but do not…
How to apply
- Read the full notice and attachments on Grants.gov. The notice is the official source for deadlines and requirements.
- Make sure your organization has an active SAM.gov registration and Unique Entity ID; registration can take several weeks.
- Register on Grants.gov and submit through Workspace before the deadline and time given in the notice. Our application guide walks through each step.
Questions go to Centers for Disease Control and Prevention - ERA, jcy5@cdc.gov, 404-498-2015.
Questions people ask
Who can apply for Cooperative Research Agreements Related to the World Trade Center Health Program (U01)?
Centers for Disease Control and Prevention - ERA accepts applications from any type of organization. The notice adds further conditions, so read its eligibility section.
What is the deadline for Cooperative Research Agreements Related to the World Trade Center Health Program (U01)?
Closes December 8, 2026 (38 days left). Confirm the date and time in the official notice on Grants.gov.
How much funding is available?
Awards of up to $550,000 each. About $49.5 million in total across about 30 awards.
Similar open grants
- Continuation of the Collaborative Islet Transplantation Registry (U01 Clinical Trial Not allowed)
- BRAIN Initiative Cell Atlas Network (BICAN): Coordinating Unit for Biostatistics, Informatics, and Engagement (CUBIE)
- Centers without Walls for mechanisms of neurodegeneration in Alzheimer’s disease-related dementias (ADRD)
- Expanding the Therapeutic Pipeline for Treating and Preventing Alzheimer's Disease and Related Dementias: Preclinical Validation and Drug Discovery for Novel Candidate Targets (U01 Clinical Trial Not Allowed)
- Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE, RP1 Clinical Trial Not Allowed)
- Exposomic Contributions to ADRD Pathology and Resilience